Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

5.51
-0.0550-0.99%
Post-market: 5.50-0.0050-0.09%16:59 EDT
Volume:2.21M
Turnover:12.13M
Market Cap:810.33M
PE:-9.39
High:5.56
Open:5.55
Low:5.39
Close:5.56
52wk High:6.60
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:0.97
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:6.50
PE(LYR):-10.39

Loading ...

Aclaris Therapeutics Q1 net loss widens on higher R&D spending

Reuters
·
May 07

BRIEF-Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16

Reuters
·
May 07

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

GlobeNewswire
·
May 07

Aclaris Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 06

Aclaris Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
May 05

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

TIPRANKS
·
May 05

Aclaris Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
May 05

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Reuters
·
May 05

Aclaris Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 04

JTL Industries Wins ACRS Nod, Tightens Grip on Global Structural Steel Markets

TIPRANKS
·
May 04

Aclaris Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Apr 30

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

TIPRANKS
·
Apr 29

Wedbush Raises Price Target on Aclaris Therapeutics to $10 From $8, Keeps Outperform Rating

MT Newswires Live
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

BRIEF-Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055

Reuters
·
Apr 28

Aclaris Therapeutics Inc - Enrollment Ongoing in Phase 1B Trials of ATI-052; Top Line Results Expected H2 2026

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc - ATI-052 Well Tolerated With Favorable Safety Profile in Phase 1a Trial

THOMSON REUTERS
·
Apr 28

Aclaris Therapeutics Inc: No Impact of Anti-Drug Antibodies (Ada) on Pk or Pd Has Been Observed in This Trial

THOMSON REUTERS
·
Apr 28

BML Capital’s Braden Leonard sells 300,000 Aclaris shares for $1.36 million

Reuters
·
Apr 28

Aclaris to release Phase 1a ATI-052 trial results April 28

Reuters
·
Apr 28